Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2010

View Archived Issues

Truvada well tolerated in HIV-1-infected pregnant women and neonates

QNL-111 shown to inhibit HIV-1 DNA integration

Vicriviroc does not meet primary endpoint in two phase III trials in HIV

C5A inhibits HIV-1 and HSV in preclinical studies

Pfizer describes novel kappa opioid receptor antagonists

Novel serotonin 5-HT6 receptor antagonists patented by Janssen

Bristol-Myers Squibb discloses new transcription factor AP-1 inhibitors

Merck KGaA identifies novel PDK1 inhibitors

Ambit Biosciences claims novel Janus kinase inhibitors

Novel dual PI3K alpha and mTOR inhibitors described by S*BIO

Resverlogix activates first site in phase II ASSURE 1 trial of RVX-208 in ACS

Fourth quarter highlights at Merck & Co.

Adeona completes 50% of enrollment in Trimesta trial in multiple sclerosis

GlycoVaxyn begins clinical trial of bioconjugate GVXN-SD-133 Shigella vaccine

Akebia initiates phase Ib trial of AKB-6548 for anemia

Fluticasone nasal spray ineffective in irritant rhinitis in pilot trial

TMTI awards SIGA contract for development broad-spectrum antiviral ST-669

Global Health Ventures to begin European trials of X-Excite for erectile dysfunction

Corcept Therapeutics begins phase I CORT-108297 trial

Rockwell Medical reports phase IIb data on soluble ferric pyrophosphate

Johnson & Johnson reviews fourth quarter of 2009

Actelion reports on BUILD-3 trial of bosentan in idiopathic pulmonary fibrosis

FDA issues refuse to file letter to Adventrx on vinorelbine NDA

Virginia G. Piper Cancer Center and TGen begin phase I trial of Pharmacyclics' PCI-32765 in cancer

FDA grants marketing approval for Shire's VPRIV for type 1 GD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...